Edition:
United Kingdom

Athenex Inc (ATNX.OQ)

ATNX.OQ on NASDAQ Stock Exchange Global Select Market

16.06USD
24 Apr 2018
Change (% chg)

$-0.10 (-0.62%)
Prev Close
$16.16
Open
$16.21
Day's High
$16.36
Day's Low
$15.96
Volume
57,617
Avg. Vol
141,204
52-wk High
$20.43
52-wk Low
$11.25

Select another date:

Thu, Feb 15 2018

BRIEF-Athenex Meets Enrollment Target For Late Stage Breast Cancer Trial

* ATHENEX MEETS ENROLLMENT TARGET FOR ORAXOL PHASE III CLINICAL TRIAL IN METASTATIC BREAST CANCER

BRIEF-Athenex Says Patient Enrollment For Two Late Stage Studies Of Actinic Keratosis Treatment Completed

* ATHENEX ANNOUNCES EARLY COMPLETION OF PATIENTS ENROLLMENT FOR TWO PHASE III CLINICAL STUDIES OF KX2-391 OINTMENT FOR ACTINIC KERATOSIS Source text for Eikon: Further company coverage:

BRIEF-Athenex Announces Pricing Of Offering Of Common Stock

* ATHENEX, INC. ANNOUNCES PRICING OF OFFERING OF COMMON STOCK

BRIEF-Athenex Announces Proposed Offering Of Common Stock

* SAYS OFFERING 4.30 MILLION COMMON SHARES Source text for Eikon: Further company coverage:

BRIEF-Athenex Announces Encouraging Early Clinical Efficacy And Safety Data Of Oraxol

* ATHENEX ANNOUNCES ENCOURAGING EARLY CLINICAL EFFICACY AND SAFETY DATA OF ORAXOL IN CLINICAL TRIAL FOR THE TREATMENT OF BREAST CANCER

BRIEF-Athenex Files For Offering Of Up To 4.3 Million Shares

* ATHENEX INC FILES FOR OFFERING OF UP TO 4.3 MILLION SHARES - SEC FILING Source text : (http://bit.ly/2Dr3FzB) Further company coverage:

BRIEF-Athenex Announces`Results Of First Cohort Of Phase I Clinical Trial Of Gastric Cancer Treatment

* ATHENEX ANNOUNCES ENCOURAGING RESULTS OF THE FIRST COHORT OF PHASE I CLINICAL TRIAL OF ORAXOL AND CYRAMZA® (RAMUCIRUMAB) COMBINATION TREATMENT IN GASTRIC CANCER Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

BRIEF-Athenex Receives Positive Feedback From FDA On The Design Of Phase III Clinical Trial For Oraxol

* ATHENEX RECEIVES POSITIVE FEEDBACK FROM FDA ON THE DESIGN OF PHASE III CLINICAL TRIAL FOR ORAXOL

BRIEF-Athenex Announces Chinese FDA Allowance Of Investigational New Drug Application Of Oraxol To Begin Clinical Trials

* ATHENEX ANNOUNCES CHINESE FDA ALLOWANCE OF INVESTIGATIONAL NEW DRUG APPLICATION OF ORAXOL TO BEGIN CLINICAL TRIALS

BRIEF-Athenex Receives Promising Innovative Medicine Designation From The UK MHRA For Oraxol

* ATHENEX RECEIVES PROMISING INNOVATIVE MEDICINE DESIGNATION FROM THE UNITED KINGDOM MHRA FOR ORAXOL, AN INNOVATIVE ORAL FORM OF PACLITAXEL Source text for Eikon: Further company coverage:

Select another date: